Tag: big pharma

RFK Jr. Torches Democrat Senator Elizabeth Warren During Hearing on TrumpRx Drug Price Cuts

HHS Secretary RFK Jr. appeared on Capitol Hill for two hearings on Wednesday.

RFK Jr. first testified before the Senate Finance Committee on his agency’s budget and the deals that the Trump Administration struck with drug companies to lower prices.

Democrat Senator Elizabeth Warren tried to go after RFK Jr. over TrumpRx’s price cuts, but he shut her down.

In February, President Trump launched ‘TrumpRx’ to lower drug prices.

“Today, President Donald J. Trump announced the launch of TrumpRx.gov. Through the website, patients will be able to access large discounts on many of the most popular and highest-priced medicines in the country, paying prices in line with the lowest paid by other developed nations (known as the most-favored-nation, or MFN, price),” the White House announced in February.

“Today’s launch features drugs made by the first five manufacturers to reach MFN pricing deals with the Trump Administration: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer,” the White House said.

“Additional drugs from other companies that have signed MFN pricing deals will be made available through TrumpRx.gov in the coming months,” they said.

TrumpRx lowers prices for popular weight loss drugs such as Ozempic and Wegovy, inhalers, fertility drugs, and insulin.

Elizabeth Warren, a corrupt and worthless Democrat who has spent decades enriching herself by lying about being a Native American, tried to come at RFK Jr. about TrumpRx.

“If these pharma deals are so good, show them!” Warren said to RFK Jr.

“You had the power to make this deal yourself! Why didn’t you do that? We did this because you refuse to do it!” RFK Jr. said.

“You have a lot more power to negotiate than we do! We got the lowest prices in history,” he said.

Elizabeth Warren hit back and claimed TrumpRx is making things worse for the American people.

“Millions of people who are using Trump Rx disagree with you!” RFK Jr. said.

Keep reading

FOIA Data Reveal Adverse Event Patterns in New RNA Dog Vaccine

Details from a FOIA request to the USDA have revealed severe adverse events following injection of the Nobivac NXT canine flu H3N2 vaccine, the first self-amplifying RNA (saRNA) vaccine widely used in the US for pets. The aftermarket reports received by The HighWire show the first 1,012 pages of 1,888 total pages of adverse events from September 2024 through July 2025. There were 296 cases involving the Nobivac RNA vaccine as a suspect product: 152 were adverse reactions, and 76 were listed as cases of lack of efficacy, meaning the dogs developed respiratory illness or cough after receiving the vaccine.

The dataset shows that there were four canine deaths and one feline death following vaccine administration, but two of the dog cases had significant confounding factors. The other two cases involve dogs that collapsed shortly after receiving the vaccination. In addition, three dogs were euthanized following the vaccine.

-41 cases involved neurological issues

-30 cases of anaphylaxis or hypersensitivity

-52 cases involved vomiting

-19 cases had an injection-site mass/lump/panniculitis/fibrosis/surgery

-26 cases of diarrhea

-5 cases of collapse/shock-type presentations

-4 cases of bloody diarrhea

A 4-year-old golden retriever collapsed 10 minutes after the vaccination, before going into complete cardiac arrest and dying. Merck added anaphylaxis to the report later. A 7-year-old Yorkshire Terrier collapsed 70 minutes after receiving the vaccine, and life-saving care was attempted, but the dog passed away. Diphenhydramine and dexamethasone sodium phosphate were given to the terrier because of previous unspecified vaccine reactions. In addition to the Nobivac flu shot, the 7.33-pound terrier received the Nobivac Canine 1-DAPPvL4 and Nobivac Intra-Trac3 vaccines.

An 8-year-old Shih Tzu was lethargic and vomiting shortly after receiving the vaccination. She was diagnosed with renal failure six days later and euthanized. The event narrative explains that she had received several vaccinations before, including non-Nobivac flu vaccines, but had never received the Nobivac NXT canine influenza vaccine, which is the first approved saRNA vaccine in the country. Merck evaluated this case and said the vaccine was unlikely to be the cause.

saRNA vaccines have limited long-term safety data, much as mRNA vaccines did before they were rolled out to the general public in response to the COVID-19 pandemic. These vaccines are marketed as “innovative, adjuvant-free, non-live vaccines” by Merck.

The first vaccine of its kind was approved by the USDA in 2024 and received limited coverage, but Nicolas Hulscher, MPH of the McCullough Foundation, criticized the lack of safety testing and the manufacturer’s level of transparency.

“It appears that Merck is attempting to camouflage the fact that this product is self-amplifying,” Hulscher wrote. “The primary product description only indicates that it uses ‘revolutionary RNA particle technology.’ However, the novel platform works by RNA particles targeting dendritic cells, where they self-replicate and result in sustained antigen production.“

Keep reading

Alzheimer’s Drugs Have No ‘Meaningful Effect’ on Cognitive Decline: Review

A class of Alzheimer’s drugs that have only been available for several years did not appear to have any “clinically meaningful effects,” according to a new review of clinical trial data.

Monoclonal antibodies that target plaque called amyloid beta in the brain showed little impact across 17 trials, Francesco Nonino, a neurologist and epidemiologist who directs the Unit of Epidemiology and Statistics at the IRCCS Institute of Neurological Sciences of Bologna, Italy, and co-authors wrote in the review.

“The effect of amyloid‐beta‐targeting monoclonal antibodies on cognitive function and dementia severity at 18 months in people with mild cognitive impairment or mild dementia due to Alzheimer’s disease is trivial, while on functional ability, it is small at best,” they said.

“Successful removal of amyloid from the brain does not seem to be associated with clinically meaningful effects in people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. Future research on disease‐modifying treatments for Alzheimer’s disease should focus on other mechanisms of action,” they added later.

The review covered 17 studies involving 20,342 participants. The drugs were typically compared with placebos in the trials, which were all funded by pharmaceutical companies.

The monoclonal antibodies in question were first approved by the U.S. Food and Drug Administration in 2021. They include Lecanemab, which is available in the United States and other countries and is produced by Eisai and Biogen, and Eli Lilly’s Donanemab.

Keep reading

FDA Calls On Drug Companies to Release Missing Clinical Trial Data

The Food and Drug Administration is urging pharmaceutical companies to make public data from clinical trials.

About three in 10 studies deemed highly likely to fall under mandatory reporting requirements have no results filed with the government’s clinical trial website, the FDA said on April 13. That is in line with historical estimates.

The FDA sent more than 2,200 companies and researchers messages in late March that reminded them of the requirements, the agency said on April 13.

“Far too often, companies are suppressing unfavorable clinical trial results and keeping them secret from patients and the scientific community. Those sponsoring clinical trials have an ethical obligation to make results public regardless of the data’s influence on the company’s share price,” FDA Commissioner Dr. Marty Makary said in a statement.

“Too many clinical trial sponsors and researchers are failing to report their results, leaving important information unavailable to clinicians and other researchers. If you are a doctor deciding whether or not to prescribe a medication to a patient, you deserve to have the best data about clinical studies on that medication.”

Sponsors of many clinical trials, and researchers involved with them, are required by federal law to report at least a summary of results within one year of completion. Phase 1 trials are among those excluded from the requirements.

The FDA can initiate a process when the people responsible for submitting the information fail to do so, which can lead to fines of up to $10,000. The process includes sending notices of noncompliance.

Only two such notices were sent in 2025, and the agency is declining to issue any, at least for now.

“The messages issued on March 30, 2026, represent an extra step the agency is taking to provide the relevant responsible parties with the opportunity to comply with federal law before the agency considers whether to take further regulatory action,” the FDA stated.

The agency, under Makary, has favored pressing companies to voluntarily meet its demands, including the removal of synthetic dyes from food.

“I fully support this new initiative to increase the prompt publication—as required by law—of results information from interventional studies of the medical products we regulate,” Dr. Tracy Beth Hoeg, acting director of the FDA’s Center for Drug Evaluation and Research, said in a statement.

“We hope that the thousands of messages sent to sponsors and investigators reminding them to publicly report their findings will improve patient safety and keep researchers and the public better informed of benefits and risks of new and investigational products.”

Keep reading

Pro-Vaccine Panelists: ‘We’re Losing the PR and Communications Battle’

The medical industry is losing control of the vaccine narrative, according to participants in a webinar moderated by Chelsea Clinton and organized by Unity Consortium — a group of pharmaceutical companies and pro-vaccine organizations.

Vaccine makers GSK, Merck and Sanofi, along with Big Tech platforms Reddit and Snapchat, and Spanish-language media giant Televisa Univision sponsored Wednesday’s event: “Who Influences Young People’s Health Choices? The New Conversations About Vaccines.”

Unity Consortium lists Pfizer, Merck, GSK and Sanofi among its members. Vaccine inventor Dr. Paul Offit is a member of its board of directors.

During the hour-long conversation, Clinton and the panelists criticized the growing number of parents and teens who are starting to question the safety of vaccines. They blamed the trend on increased access to what they characterized as online “misinformation” — and on organizations like Children’s Health Defense (CHD).

“What’s different today … is that people have access to a lot more information,” said Dr. Margot Savoy, chief medical officer of the American Academy of Family Physicians. “The part that makes me nervous is that, more and more, we’re getting into this odd space where people are feeling a little more polarized.”

Jessica Steier, founder and CEO of Unbiased Science and author of “The Playbook Used to ‘Prove’ Vaccines Cause Autism,” said pro-vaccine voices are “losing the PR and communications battle.”

Elisabeth Marnik, Ph.D., executive director of The Evidence Collective and author of “I Grew Up Unvaccinated. Now I’m an Immunologist,” said the circulation of and public access to such information is “one of the hardest parts about social media.”

“The more somebody sees these false claims circulating, the more likely they are to start to question their own understanding. And that’s one of the dangers of social media,” Marnik said. She said that parents’ decisions not to vaccinate their children are “a product of [this] information ecosystem.”

Clinton suggested that the ecosystem acts as a barrier to sustaining trust in the medical profession and public health. “The algorithms are part of the challenge of both … the corrosion of trust and … the barriers to replenishing and sustaining that trust,” Clinton said.

According to Marnik, the public health establishment is losing public trust because “public health and science aren’t always good storytellers.” The “anti-vaccine side” is “really good at spreading these stories that are really compelling and very scary and [that] can motivate people in ways that are harmful.”

Keep reading

New York Times does it again, pushing pro-vaccine narrative over journalism

A recent New York Times article examining Robert F. Kennedy Jr. and developments at the CDC is drawing criticism over what some describe as one-sided vaccine coverage.

The article, published March 23, relied heavily on interviews with former CDC officials and presented commonly cited claims that vaccines are safe and effective, while offering little perspective from those who question that view.

It also highlighted Kennedy’s work and advocacy, including claims that he has spread misinformation about vaccines.

The coverage pointed to a 2025 measles outbreak in a Texas community with low vaccination rates, attributing reported deaths to measles. Other accounts cited by Children’s Health Defense have raised questions about those conclusions.

The article also addressed statements about vaccine ingredients, including the use of fetal cell lines in some vaccines. Kennedy has raised concerns about the presence of human DNA fragments, which some individuals cite as a religious or ethical issue.

On autism, the article echoed the widely held view that rising diagnosis rates are largely due to expanded screening and reporting. Critics argue that explanation does not fully account for the increase.

The article further referenced concerns about what it described as “spurious harms” linked to vaccines. However, federal data show billions of dollars have been awarded through the vaccine injury compensation program.

It also cited public health positions on issues such as fluoridated drinking water and routine vaccination schedules recommended by major medical organizations.

The broader debate over vaccine mandates and informed consent was also raised, including whether individuals should have the right to decline vaccines for religious or personal reasons.

The discussion comes as vaccination rates for some vaccines have declined, religious exemptions have increased, and lawmakers consider changes to vaccine policy, including liability protections and exemption laws.

Keep reading

End of Federal Childhood Vaccine Incentives

Doctors will no longer receive financial rewards tied to childhood vaccination rates under key government programs. The announcement, first detailed in a December 30 memo from the Centers for Medicare & Medicaid Services (CMS), states that the agency “does not tie payment to performance on immunization quality measures in Medicaid and CHIP [the Children’s Health Insurance Program] at the federal level.” CMS urged states to discontinue similar incentives and eliminated mandatory reporting of childhood immunization data, though voluntary reporting remains an option. The memo also signaled efforts to strengthen informed consent and accommodate religious exemptions.

U.S. Health and Human Services Secretary Robert F. Kennedy, Jr. welcomed the directive, posting: “Government bureaucracies should never coerce doctors or families into accepting vaccines or penalize physicians for respecting patient choice. That practice ends now.” Advocates such as Children’s Health Defense CEO Mary Holland called it a welcome step toward treating vaccines like other medical interventions, free from metric-driven pressure. Pediatrician Dr. Michelle Perro noted that tying compensation to specific decisions can erode trust in care.

Promoting Preventive Care or Distorting Judgment?

This change comes after years of scrutiny over financial incentives in pediatric medicine. An October 2025 clip from Dr. Suzanne Humphries on The Joe Rogan Experience claimed some doctors could lose up to $250,000 annually by not meeting vaccination targets, including for Covid shots in infants. These incentives stemmed from value-based payment models under Medicaid, CHIP, and private insurers. Practices received bonuses or higher reimbursements for hitting coverage benchmarks (e.g., percentages of patients vaccinated). One analysis of an Oregon pediatric practice projected more than $1 million in annual losses for declining CDC-scheduled vaccines, largely from administrative fees. Roughly 40 percent of U.S. children are on Medicaid, amplifying the program’s reach. During Covid, specific per-dose payments (around $45 plus administration fees) added to the structure.

Proponents of the incentives argued they promoted preventive care and reduced disease outbreaks, with insurers — not pharmaceutical companies — providing payments to lower long-term costs. Critics, however, contended the metrics distorted clinical judgment and pressured families, contributing to eroded trust and reports of patients being dismissed for declining shots.

The CMS policy applies only at the federal level; some states or private insurers may retain incentives. It is telling that pediatric organizations are pushing back against broader vaccine-policy shifts under the current administration.

Keep reading

Vaccine Amnesia: Why Did The Media Stop Covering Vaccine Disasters?

A key theme I’ve tried to highlight in this publication is that the same medical catastrophes keep repeating (because those responsible are never held accountable), so by understanding what happened in the past, you can see and understand what is happening now and what will likely happen in the future.

For example, because vaccines are “risky but necessary,” the medical profession and government, again and again, concluded that they needed to tell the public all vaccines were “safe and effective” as the potential injuries a mass vaccination campaign would cause were outweighed by “necessary” benefit the vaccines could offer. As such, examples can be found again and again of severe injuries being systematically covered up for the “greater good” (e.g., the earliest documented example I know of this happened in 1874 with the smallpox vaccine) and health authorities concocting the same set of excuses we’ve seen since smallpox as to why those vaccines failed to prevent the diseases they were supposed to.

Since the risks outweigh the benefits for most vaccines (detailed here), a mass vaccination paradigm can only be sustained by censoring all evidence of harm, and then using that absence of evidence as proof the vaccines are safe. As such, over the decades, we’ve seen more and more be done to conceal those harms.

Keep reading

FDA Grants Speedy Approval to Eli Lilly’s Weight-Loss Pill for Obesity

Federal regulators on Wednesday approved Eli Lilly’s new weight-loss pill, a second daily oral medication to treat obesity and other weight-related conditions.

The Food and Drug Administration granted expedited approval to orforglipron, a GLP-1 drug that works like widely used injectable medications to mimic a natural hormone that controls appetite and feelings of fullness.

The drug, which will be branded as Foundayo, is expected to begin shipping Monday. The company said people with insurance may be able to get the drug starting at $25 per month with a Lilly discount card. Prices for people paying cash will range between $149 per month to $349 per month, depending on the dose.

The new pill joins drugmaker Novo Nordisk’s oral Wegovy pill, which has spurred more than 600,000 prescriptions in the United States since it was approved in December.

The FDA authorized Eli Lilly’s drug as part of a new program aimed at cutting drug approval times. The agency said it reviewed the company’s application in 50 days.

In a clinical trial of more than 3,000 adults with obesity, participants who received the highest dose of orforglipron, 36 milligrams, lost 11.2% of their body weight — about 25 pounds on average — over more than 16 months. That compared with a 2.1% weight loss, or less than 5 pounds, in patients who received a placebo, or dummy pill, according to the New England Journal of Medicine.

Keep reading

Big Pharma Giants Pfizer and BioNTech Forced to Shut Down COVID-19 Booster Shot Trials After Americans Refuse to Be Guinea Pigs

Major Big Pharma companies have abruptly halted their latest COVID-19 mRNA “booster” trial because they literally couldn’t find enough willing participants.

After years of gaslighting the American public, raking in hundreds of billions in profits from experimental shots that were shoved down our throats under the guise of “public health,” the same corporations that partnered with the Biden regime, Anthony Fauci, and the lying mainstream media are now facing the cold, hard reality: Americans are done being lab rats.

According to internal letters sent to trial investigators and obtained by Reuters, Pfizer is ending its study of “updated” shots in healthy adults aged 50 to 64.

The company admitted it was “unable to generate relevant data” because recruitment had effectively hit a brick wall.

Reports indicate that more than 80% of potential recruits didn’t even make it past pre-screening, or simply refused to participate.

The trial, which aimed to enroll a massive 25,000 to 30,000 participants, folded after failing to meet even the most basic enrollment targets.

This comes at a time when the “science” is being scrutinized like never before. Under the current administration, the FDA has been pressured to actually require randomized placebo-controlled trials, the very thing skeptics have been demanding for years.

Keep reading